Miscellaneous Ocular Agents
The recommendation was based on data from the Luxturna clinical development program which included a Phase 3 trial in patients 4-44 years of age.
The researchers found that the mean total ophthalmologist examination time was 11.2 minutes per patient, of which 27% was spent on EHR use, 42% on conversation, and 31% on examination.
Mean improvement at 12 months was 8.3 letters with combination therapy compared with 5.1 letters with monotherapy, demonstrating that combination therapy met the predefined criterion for noninferiority as well as being superior to monotherapy.
The researchers found that donor rim culture results were three times more likely to be positive for fungi in endothelial keratoplasty-processed eyes (1.14%) compared with other uses (0.37%).
The researchers found that there was a statistically significant increase in plasma lutein and zeaxanthin in the lutein plus zeaxanthin group after 3 months and 6 months of treatment versus the placebo group
In 7 of 8 eyes with a normal photoreceptor layer, pericentral retina with normal lamination showed a thinned (<30% of normal thickness) ganglion cell layer (GCL) that colocalized.
The investigators found that both formulations were cost-effective for treating patients with early-stage disease, but they were even more cost-effective for those with the condition in only 1 eye.
The moon passes the sun so quickly (at 2880km/h) that most of the time individuals (even those in the direct path of totality) will be experiencing a partial eclipse, and will be exposed to the sun's core.
The triamcinolone and moxifloxacin injection was intended for use as post-op prophylaxis for ocular inflammation and endophthalmitis to eliminate the use of post-op eye drops.
One in 5 of the infants had sight-threatening eye abnormalities, with optic nerve and retinal abnormalities the most common.
Magnetic resonance imaging (T1-weighted and diffusion-weighted imaging) with a 3-T magnetic resonance imager revealed that the Parkinson's patients had significant alterations in optic radiation connectivity distribution.
Dexycu injection was developed to help compliance—especially among elderly patients—and avoid dosing errors associated with conventional treatments that depend on self-administered eye drops multiple times a day.
After adjustment for potential confounders, the risk of cataracts was lower among participants in the highest versus the lowest tertile of dietary vitamin K1 intake (hazard ratio, 0.71).
The researchers found that in the intention-to-treat population, 69 and 20% of those who received teprotumumab and placebo, respectively, had a response at week 24.
Researchers conducted a secondary analysis of data from a comparative effectiveness trial for center-involved DME in 650 participants during 2 years of treatment with aflibercept (2mg), bevacizumab (1.25mg), or ranibizumab (0.3mg).
Children with active JIA-associated uveitis who were taking a stable dose of methotrexate were randomly assigned to either adalimumab or placebo for 2 weeks.
The researchers observed an increase in cone-like cells after switching rod to cone-like photoreceptors in situ by inactivation of Nrl or Nr2e3.
The analysis indicated that patients with and without DME in the Lucentis treatment group had improvements in the severity of their retinopathy.
The researchers assessed the cardiovascular and cerebrovascular safety of ranibizumab 0.3mg and 0.5mg vs. sham with and without laser in diabetic macular edema.
The researchers found that early AMD was associated with a small reduction in VSF compared with no AMD in adjusted models in a group of ethnic Chinese but not in groups of ethnic Indians or Malays.
The finished product is still some way off being consumer-ready, but when complete it could restore sight to millions of people with degenerative eye diseases.
Young children should be screened at least once for amblyopia before they turn 5 years old, according to a draft recommendation statement issued by the U.S. Preventive Services Task Force.
Valeant have re-submitted their NDA for latanoprostene bunod ophthalmic solution after receiving a Complete Response Letter from the FDA last summer.
The NDA for Dextenza was resubmitted in January 2017 following a Complete Response Letter that was issued in July 2016 due to concerns with deficiencies in manufacturing processes and controls.
To reduce the risk or slow the progression of of diabetic retinopathy, the guidelines recommend optimizing glycemic control, as well as lowering blood pressure and serum lipids.